ADMA stock, which ranks second on the IBD 50, plummeted Thursday after the biotech company slightly missed the Street's first-quarter expectations.
ADMA Biologics uses donated plasma to make immunoglobulin products that treat patients with compromised immune systems. During the three months ended March 31, ADMA earned an adjusted 14 cents per share and had $114.8 million in sales. Earnings jumped nearly 36% vs. the year-earlier period, while sales rose 40%.
But earnings missed expectations by a penny and sales lagged analysts' call for $116.4 million.
ADMA stock tumbled 10.2% to 21.20. Shares briefly undercut their 50-day line but managed to retake that key point by the close, according to MarketSurge.
Analysts Positive On ADMA Stock
Mizuho Securities analyst Anthony Petrone remained confident in ADMA stock. He raised his price target to 35 from 32.
Though sales missed the average estimate of four analysts polled by FactSet, they beat Petrone's call by $3 million. Adjusted earnings before interest, taxes, depreciation and amortization reached another new record high, he said in a report.
More patients are starting to use ADMA's homegrown product, Asceniv. Asceniv is a collection of antibodies that can protect patients from respiratory syncytial virus, or RSV. The virus tends to cause coldlike symptoms in most people, but it can be serious in people with immunodeficiencies.
Petrone noted Bivigam is also gaining share in the core immunoglobulin space. Bivigam includes antibodies that protect against an array of common viruses.
ADMA Raises Its Sales Outlook
ADMA raised its sales outlook for 2025 and 2026. The company calls for a respective $500 million and $625 million in sales. Analysts currently project $508.2 million this year and $640.9 million in next year's sales.
"Importantly, this latest guidance raise is all organic as the recently secured FDA clearance for Ig (immunoglobulin) yield enhancement is still not fully baked," Petrone said, referring to a new manufacturing process that ADMA says will boost its immunoglobulin production by 20%.
ADMA stock ranks second on the IBD 50 list of elite growth stocks behind fellow medical company Hims & Hers Health. Shares of ADMA have strong IBD Digital Composite and Relative Strength ratings of 98. This means they outrank 98% of all stocks when it comes to fundamental and technical measures and 12-month performance.
Following the earnings report, analysts with Raymond James and Cantor Fitzgerald also raised their price targets on ADMA stock.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
